Testosterone blends
Multi-ester testosterone blends (four-ester and similar preparations)
Written by Aaron CuhaReviewed Sep 2026
Also known as: Sustanon, Sustanon 250, Four-ester testosterone, Omnadren
One vial holding several testosterone esters with different release rates. Harder to reason about and harder to time bloodwork around, for a convenience benefit that weekly dosing of a single ester largely removes.
Overview
If you were handed a vial described as a blend of four testosterones, this is the page. The best-known is a preparation combining a short ester with two intermediate ones and a long one, and the design intent was to smooth the release curve: the short ester acts within a day or two while the long one carries the back end, so a single injection covers a longer interval.
The hormone is the same in all of them. Every ester cleaves to identical testosterone, so a blend is not four different drugs, it is one drug released at four rates from one syringe.
The practical problem is that a mixed release curve is harder to reason about than a single one, and it makes a blood level harder to interpret, because the result depends on which esters are still releasing at the moment of the draw. The design solved a problem that weekly or split dosing of a single ester solves more transparently, which is why a single ester is the more common choice today.
Mechanism of action
Several testosterone esters of differing chain length dissolved together in one oil vehicle. Shorter chains are cleaved by tissue esterases sooner and longer chains later, so the preparation releases free testosterone over a wider window than any single ester would. The released hormone is identical regardless of which ester carried it. Note the consequence for dosing: the labelled milligram figure is the total of all esters, and because ester molecules carry weight that is not testosterone, the actual testosterone delivered is less than the number on the label, and differs between esters.
Human evidence
Long clinical use in countries where these preparations are licensed. The hormone's evidence base applies; what is thin is any comparison of a blend against a single ester on symptoms or stability.
- The delivered hormone is identical to that from any other testosterone preparation, so the efficacy and safety evidence for testosterone applies.
- The release profile spans a range rather than following one curve, which was the design intent.
- No trial was located comparing a multi-ester blend against a single ester at matched dosing on symptom stability or on any clinical endpoint.
- Interpretation of a blood level is harder, because the result depends on which esters are still releasing when blood is drawn.
- The labelled milligram figure is the combined ester mass and overstates the testosterone actually delivered.
What this does not tell you: The central limit is comparative: nobody has tested whether a blend produces steadier levels or better symptoms than weekly or split dosing of a single ester, which is the comparison that would justify the added complexity. In the United States these preparations are not approved, so anything sold under these names is compounded or grey-market and its actual composition is not verified by any regulator, which makes every statement above about release profile an assumption about what is in the vial.
Reading the research record
The honest assessment of multi-ester blends is that they solve a problem that has a simpler solution.
The design made sense when the alternative was an infrequent injection of a single long ester: combine a fast ester for early coverage with a slow one for the back end and you get a wider window from one shot. But the modern answer to peak-to-trough swing is not a cleverer vial, it is a shorter interval. Weekly or split dosing of a single ester achieves a flatter curve and leaves you with one release rate to reason about, one half-life, and a blood level that means something.
There is also a specific practical warning for anyone in the United States. These preparations are not approved there, so a vial carrying one of these names came from compounding or from the grey market, and nothing verifies that its contents match the label. Every claim about how a blend releases assumes the blend is what it says it is. That assumption is doing more work than most people realise, and this site's supplement quality section documents how often such assumptions fail when anyone checks.
The evidence, charted
Fig. 1 · evidence composition
1of 2 citations (50%) are in people
Counted from the citation list on this page. The Human count is the same number shown in the badge at the top. Both understate any literature larger than the sources we cite.
Fig. 2 · evidence over time
Citations here span just two years, 2023 and 2026.
Too few distinct publication years on this page to plot as a timeline.
Fig. 3 · legal status at a glance
US
Not approved
UK
Approved
AU
Approved
CA
Approved
Approved in 3 of 4, prescription route in 0, not approved in 1. A jurisdiction's classification is a regulatory fact, not a verdict on the science; see Legal status below for the full text and any notes.
Fig. 4 · dose response
No human dose response curve exists
We draw this figure where the data supports it. For this compound in humans it does not, so the panel stays empty rather than borrowing an animal curve and implying it transfers.
Key studies & citations
- Review2026
Individualizing injectable testosterone replacement therapy in primary care: pharmacokinetics, symptom stability, safety monitoring, and injection interval
The reason this page exists. The guidance asks clinicians to document the testosterone ester, dose, concentration, route, injection interval, timing of the last injection and timing of bloodwork, because without that context testosterone results can be misleading. A blend makes the first of those a list rather than a single fact, which is precisely what makes interpretation harder.
Cureus - Human2023
Cardiovascular safety of testosterone-replacement therapy
TRAVERSE. The safety evidence for testosterone replacement is about the hormone rather than the ester, so it applies here, with the qualifier that the trial used a transdermal gel titrated to a defined range.
New England Journal of Medicine
Frequently asked questions
My doctor put me on a blend of four testosterones. What is it?
One drug delivered at several rates. Each ester cleaves to identical testosterone, so the blend is not four hormones; it is testosterone attached to four different chains that release over different windows, from about a day for the shortest to a couple of weeks for the longest. The design intent was to cover a longer interval from a single injection.
Is a blend better than plain cypionate?
No trial has compared them on symptoms or stability, so there is no evidence-based answer. The reasoning favours a single ester: one release rate is easier to time, easier to draw bloodwork around, and weekly or split dosing achieves a flat curve without needing a mixed preparation.
Why is my blood test hard to interpret on a blend?
Because the number depends on which esters are still releasing when the blood was drawn, and there are several overlapping curves rather than one. The practice guidance asks for the ester, dose, route, interval and timing of the last injection to be recorded alongside the result, and on a blend the first of those is a list.
Is the milligram number on the label the testosterone dose?
No, and this trips people up. The label figure is the combined mass of the esters, and the ester chains carry weight that is not testosterone. The hormone actually delivered is less than the labelled number, and by a different amount for each ester.